Illumina (ILMN)

• Market cap: $21.7B
• 1 day: -0.51%
• 5 days: -0.24%
• 1 month: -4.51%
• 3 months: -4.77%
• 6 months: 14.00%
• Year to date: 4.38%
• 1 year: 2.33%
• 5 years: -57.91%
• 10 years: -30.53%
• Sector: Industrials
• Industry: Laboratory Analytical Instruments

About: Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2023 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Employees: 9,300

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

56% more funds holding in top 10

Funds holding in top 10: 9 [Q2] → 14 (+5) [Q3]

39% more first-time investments, than exits

New positions opened: 139 | Existing positions closed: 100

23% more capital invested

Capital invested by funds: $14.9B [Q2] → $18.4B (+$3.49B) [Q3]

4% more funds holding

Funds holding: 756 [Q2] → 787 (+31) [Q3]

1% more repeat investments, than reductions

Existing positions increased: 273 | Existing positions reduced: 269

1.09% less ownership

Funds ownership: 89.82% [Q2] → 88.73% (-1.09%) [Q3]

13% less call options, than puts

Call options by funds: $174M | Put options by funds: $199M

Research analyst outlook

11 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $139 2% upside
• Avg. target: $166 22% upside
• High target: $254 86% upside

11 analyst ratings

• positive: 4 36%
• neutral: 7 64%
• negative: 0 0%

Morgan Stanley Tejas Savant 29% 1-year accuracy 4 / 14 met price target	10% upside $150	Equal-Weight Maintained	13 Jan 2025
Citigroup Patrick Donnelly 47% 1-year accuracy 15 / 32 met price target	21% upside $165	Neutral Downgraded	11 Dec 2024
Stephens & Co. Mason Carrico 68% 1-year accuracy 13 / 19 met price target	35% upside $184	Overweight Maintained	12 Nov 2024
Piper Sandler David Westenberg 67% 1-year accuracy 26 / 39 met price target	35% upside $185	Overweight Maintained	11 Nov 2024
Baird Catherine Ramsey 83% 1-year accuracy 10 / 12 met price target	2% upside $139	Neutral Maintained	6 Nov 2024